Piroxicam selectively inhibits the growth of premalignant and malignant human oral cell lines by limiting their progression through the S phase and reducing the levels of cyclins and AP-1

International Journal of Cancer

Volumn 107, Issue 5, 2003, Pages 830-836

  Ding, Haiming ^a   Han, Chunhua ^a   Gibson D'Ambrosio, Ruth ^a   Steele, Vernon E ^b   D'Ambrosio, Steven M ^a,c,d  

^a OHIO STATE UNIVERSITY   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d NONE   (United States)

Author keywords

AP 1; Cyclin dependent kinase; Cyclins; Oral cancer; Piroxicam; S phase

Indexed keywords

CELL CYCLE PROTEIN; CYCLIN A; CYCLIN B1; CYCLIN D1; CYCLINE; CYCLOOXYGENASE 1; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; PROSTAGLANDIN E2; PROSTAGLANDIN SYNTHASE; PROTEIN C JUN; PROTEIN CDC2; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG;

ARTICLE; CANCER INHIBITION; CANCER MORTALITY; CANCER RISK; CELL CYCLE S PHASE; CELL GROWTH; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG MECHANISM; DRUG SPECIFICITY; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; HUMAN TISSUE; MOUTH CANCER; NORMAL HUMAN; PRECANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; TRANSGENE;

BASE SEQUENCE; BROMODEOXYURIDINE; CELL DIVISION; CELL LINE; CELL SURVIVAL; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; DNA PRIMERS; HUMANS; MOUTH MUCOSA; MOUTH NEOPLASMS; PIROXICAM; POLYMERASE CHAIN REACTION; PRECANCEROUS CONDITIONS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR CELLS, CULTURED;

EID: 0242332090     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.11499     Document Type: Article

References (54)

1. Reddy BS, Rao CV. Novel approaches for colon cancer prevention by cyclooxygenase-2 inhibitors. J Environ Pathol Toxicol Oncol 2002; 21:155-64.
2. Jolly K, Cheng KK, Langman MJ. NSAIDs and gastrointestinal cancer prevention. Drugs 2002;62:945-56.
3. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002;94:252-66.
4. Kelloff GJ, Crowell JA, Steele VE, Lubet RA, Boone CW, Malone WA, Hawk ET, Lieberman R, Lawrence JA, Kopelovich L, Ali I, Viner JL, et al. Progress in cancer chemoprevention. Ann NY Acad Sci 1999;889:1-13.
5. Perkins TM, Shklar G. Delay in hamster buccal pouch carcinogenesis by aspirin and indomethacin. Oral Surg Oral Med Oral Pathol 1982;53:170-8.
6. Moran EM. Epidemiological and clinical aspects of nonsteroidal anti-inflammatory drugs and cancer risks. J Environ Pathol Toxicol Oncol 2002;21:193-201.
7. Tegeder I, Pfeilschifter J, Geisslinger G. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J 2001;15:2057-72.
8. Vainio H. Is COX-2 inhibition a panacea for cancer prevention? Int J Cancer 2001;94:613-4.
9. Raz A. Is inhibition of cyclooxygenase required for the anti-tumorigenic effects of nonsteroidal, anti-inflammatory drugs (NSAIDs)? In vitro versus in vivo results and the relevance for the prevention and treatment of cancer. Biochem Pharmacol 2002;63:343-7.
10. Minter HA, Eveson JW, Huntley S, Elder DJ, Hague A. The cyclooxygenase 2-selective inhibitor NS398 inhibits proliferation of oral carcinoma cell lines by mechanisms dependent and independent of reduced prostaglandin E2 synthesis. Clin Cancer Res 2003;9:1885-97.
11. Fournier DB, Gordon GB. COX-2 and colon cancer: potential targets for chemoprevention. J Cell Biochem 2000;(Suppl 34):97-102.
12. Yip-Schneider MT, Barnard DS, Billings SD, Cheng L, Heilman DK, Lin A, Marshall SJ, Crowell PL, Marshall MS, Sweeney CJ. Cyclooxygenase-2 expression in human pancreatic adenocarcinomas. Carcinogenesis 2000;21:139-46.
13. Molina MA, Sitja-Arnau M, Lemoine MG, Frazier ML, Sinicrope FA. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res 1999;59:4356-62.
14. Goldman AP, Williams CS, Sheng H, Lamps LW, Williams VP, Pairet M, Morrow JD, DuBois RN. Meloxicam inhibits the growth of colorectal cancer cells. Carcinogenesis 2003;19:2195-9.
15. Sheng H, Shao J, Kirkland SC, Isakson P, Coffey RJ, Morrow J, Beauchamp RD, DuBois RN. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest 1997;99:2254-9.
16. Grosch S, Tegeder I, Niederberger E, Brautigam L, Geisslinger G. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB J 2001;15:2742-4.
17. Neville BW, Day TA. Oral cancer and precancerous lesions. CA Cancer J Clin 2002;52:195-215.
18. Mao L. Leukoplakia: molecular understanding of pre-malignant lesions and implications for clinical management. Mol Med Today 1997;3:442-8.
19. Lee MH, Yang HY. Negative regulators of cyclin-dependent kinases and their roles in cancers. Cell Mol Life Sci 2001;58:1907-22.
20. Carnero A. Targeting the cell cycle for cancer therapy. Br J Cancer 2002;87:129-33.
21. Michalides RJ, van de Brekel M, Balm F. Defects in G1-S cell cycle control in head and neck cancer: a review. Head Neck 2002;24:694-704.
22. D'Ambrosio SM, Gibson-D'Ambrosio RE, Chang MJW, Kelloff GJ, Steele VE. Identification and molecular targets of new anticancer agents directed at human oral cancer cells. Anticancer Res 2001;21: 1585-6.
23. D'Ambrosio SM, D'Ambrosio REG, Milo GE, Casto BC, Kelloff GJ, Steele VE. Differential growth responses of normal, premalignant, and malignant human oral epithelial cells by chemopreventive agents. Anticancer Res 2000;20:2273-80.
24. Gibson-D'Ambrosio RE, Samuel M, D'Ambrosio SM. A method for isolating large numbers of viable disaggregated cells from various human tissues for cell culture establishment. In Vitro Cell Dev Biol 1986;22:529-34.
25. Milo GE, Shuler C, Kurian P, French BT, Mannix DG, Noyes I, Hollering J, Sital N, Schuller DE, Trewyn RW. Nontumorigenic squamous cell carcinoma line converted to tumorigenicity with methyl methanesulfonate without activation of HRAS or MYC. Proc Natl Acad Sci USA 1990;87:1268-72.
26. Hanif R, Pittas A, Feng Y, Koutsos MI, Qiao L, Staiano-Coico L, Shiff SI, Rigas B. Effects of nonsteroidal anti-inflammatory drugs on proliferation and on induction of apoptosis in colon cancer cells by a prostaglandin-independent pathway. Biochem Pharmacol 1996;52: 237-45.
27. Kawamoto T, Shoda J, Asano T, Ueda T, Furukawa M, Koike N, Tanaka N, Todoroki T, Miwa M. Expression of cyclooxygenase-2 in the subserosal layer correlates with postsurgical prognosis of pathological tumor stage 2 carcinoma of the gallbladder. Int J Cancer 2002;98:427-34.
28. Hennigan RF, Stambrook PJ. Dominant negative c-jun inhibits activation of the cyclin D1 and cyclin E kinase complexes. Mol Biol Cell 2001;12:2352-63.
29. Shaulian E, Karin M. AP-1 in cell proliferation and survival. Oncogene 2001;20:2390-400.
30. Murakami M, Nakatani Y, Tanioka T, Kudo I. Prostaglandin E synthase. Prostaglandins Other Lipid Mediat 2002;68/69:383-99.
31. Qiao L, Kozoni V, Tsioulias G, Koutsos M, Hanif R, Shiff S. Rigas B. Selected eicosanoids increase the proliferation rate of human colon carcinoma cell lines and mouse colonocytes in vivo. Biochim Biophys Acta 1995;1258:215-23.
32. Yano T, Zissel G, Muller-Qernheim J, Jae Shin S, Satoh H, Ichikawa T. Prostaglandin E2 reinforces the activation of Ras signal pathway in lung adenocarcinoma cells via EP3. FEBS Lett 2002;518:154-8.
33. 2 protects intestinal tumors from nonsteroidal anti-inflammatory drug-induced regression in Apc(Min/+) mice. Cancer Res 2002;62:403-8.
34. Sumitani K, Kamijo R, Toyoshima T, Nakanishi Y, Takizawa K, Hatori M, Nagumo M. Specific inhibition of cyclooxygenase-2 results in inhibition of proliferation of oral cancer cell lines via suppression of prostaglandin E2 production. J Oral Pathol Med 2001;30:41-7.
35. Yamazaki R, Kusunoki N, Matsuzaki T, Hashimoto S, Kawai S. Selective cyclooxygenase-2 inhibitors show a differential ability to inhibit proliferation and induce apoptosis of colon adenocarcinoma cells. FEBS Lett 2002;531:278-84.
36. Mohammed SI, Bennett PF, Craig BA, Glickman NW, Mutsaers AJ, Snyder PW, Widmer WR, DeGortari AE, Bonney PL, Knapp DW. Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Cancer Res 2002;62:356-8.
37. ElAttar T, Lin HS. Inhibition of human oral squamous carcinoma cell (SCC-25) proliferation by prostaglandin E2 and vitamin E succinate. J Oral Pathol Med 1993;22:425-7.
38. Williams CS, Mann M, DuBois RN. The role of cyclooxygenases in inflammation, cancer, and development. Oncogene 1999;18:7908-16.
39. Narumiya S, Sugimoto Y, Ushikubi F. Prostanoid receptors: structures, properties, and functions. Physiol Rev 1999;79:1193-226.
40. Rose BR, Thompson CH, Tattersall MH, O'Brien CJ, Cossart YE. Squamous carcinoma of the head and neck: molecular mechanisms and potential biomarkers. Aust N Z J Surg 2000;70:601-6.
41. Dictor M, Ehinger M, Mertens F, Akervall J, Wennerberg J. Abnormal cell cycle regulation in malignancy. Am J Clin Pathol 1999;112: S40-52.
42. King KL, Cidlowski JA. Cell cycle regulation and apoptosis. Annu Rev Physiol 1998;60:601-17.
43. Kawamoto H, Koizumi H, Uchikoshi T. Expression of the G2-M checkpoint regulators cyclin B1 and cdc2 in nonmalignant and malignant human breast lesions: immunocytochemical and quantitative image analyses. Am J Path 1997;150:15-23.
44. Nojima H. Cell cycle checkpoints, chromosome stability and the progression of cancer. Human Cell 1997;10:221-30.
45. Dong Y, Sui L, Tai Y, Sugimoto K, Tokuda M. The overexpression of cyclin-dependent kinase (CDK) 2 in laryngeal squamous cell carcinomas. Anticancer Res 2001;21:103-8.
46. Quon H, Liu FF, Cummings BJ. Potential molecular prognostic markers in head and neck squamous cell carcinomas. Head Neck 2001;23: 147-59.
47. Liu SC, Klein-Szanto AJ. Markers of proliferation in normal and leukoplakic oral epithelia. Oral Oncol 2000;36:145-51.
48. Hassan K, Ang K, El-Naggar A, Story M, Lee J, Liu D, Hong W, Mao L. Cyclin B1 overexpression and resistance to radiotherapy in head and neck squamous cell carcinoma. Cancer Res 2002;62:6414-7.
49. Bukholm I, Bukholm G, Nesland J. Coexpression of cyclin A and beta-catenin and survival in breast cancer patients. Int J Cancer 2001;94:148-9.
50. Opitz O, Harada H, Suliman Y, Rhoades B, Sharpless N, Kent R, Kopelovich L, Nakagawa H, Rustgi A. A mouse model of human oral-esophageal cancer. J Clin Invest 2002;110:761-9.
51. Warbrick E. The puzzle of PCNA's many partners. Bioessays 2000; 22:997-1006.
52. Gibbs E, Pan Z, Niu H, Hurwitz J. Studies on the in vitro phosphorylation of HSSB-p34 and -p107 by cyclin-dependent kinases. Cyclin-substrate interactions dictate the efficiency of phosphorylation. J Biol Chem 1996;271:22847-54.
53. Krek W, Xu G, Livingston DM. Cyclin A-kinase regulation of E2F-1 DNA binding function underlies suppression of an S phase checkpoint. Cell 1995;83:1149-58.
54. Guo Y, Stacey DW, Hitomi M. Post-transcriptional regulation of cyclin D1 expression during G2 phase. Oncogene 2002;21:7545-56.